Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Initiating Eltrombopag (EPAG) Early for aplastic Anemia (AA) may Lead to greater clinical benefits: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

STShuai TanMSMingyue ShangJNJing Ni

Discussion

Loading...

Member takes

Overview

Meta-analysis shows early Eltrombopag combined with IST improves efficacy in aplastic anemia, suggesting optimal treatment timing.

Key Points

  • To compare Eltrombopag plus immunosuppressive therapy with immunosuppressive therapy alone in treating aplastic anemia.
  • Conducted a systematic review and meta-analysis of 21 studies
  • Used fixed effects model to calculate odds ratios and confidence intervals
  • Retrieved literature from Chinese and English databases
  • Overall response rate higher in Eltrombopag group at 3 months and 6 months
  • No significant difference in response at 12 months between groups
  • Subgroup analysis recommended early Eltrombopag for adult patients for optimal hematologic improvement.

Cite This Study

Tan et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e06ehttps://doi.org/10.1182/blood-2025-6721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1This Meta-Analysis Evaluates the Optimal Timing for Initiating and Discontinuing Eltrombopag for Aplastic Anemia2025
  2. 2A Multicenter, Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Front-Line Treatment for Pediatric Severe Aplastic Anemia.2025 · 2 citations
  3. 3Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis2025
  4. 4Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025
  5. 5Efficacy and influencing factors of immunosuppressive therapy combined with or without eltrombopag in children with severe aplastic anemia2025